vs
Side-by-side financial comparison of Arcellx, Inc. (ACLX) and ADMA BIOLOGICS, INC. (ADMA). Click either name above to swap in a different company.
ADMA BIOLOGICS, INC. is the larger business by last-quarter revenue ($139.2M vs $1.7M, roughly 84.1× Arcellx, Inc.). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs -3513.4%, a 3548.9% gap on every dollar of revenue. On growth, ADMA BIOLOGICS, INC. posted the faster year-over-year revenue change (18.4% vs -89.2%). ADMA BIOLOGICS, INC. produced more free cash flow last quarter ($34.6M vs $-58.9M). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs -79.5%).
Arcellx, Inc. is a clinical-stage biotechnology company that develops innovative chimeric antigen receptor T (CAR-T) cell therapies for treating hard-to-treat cancers including hematologic malignancies and solid tumors. Its core pipeline targets unmet oncology medical needs, serving global patient populations and partnering with life sciences stakeholders.
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
ACLX vs ADMA — Head-to-Head
Income Statement — Q4 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $1.7M | $139.2M |
| Net Profit | $-58.1M | $49.4M |
| Gross Margin | — | 63.8% |
| Operating Margin | -3850.2% | 45.1% |
| Net Margin | -3513.4% | 35.5% |
| Revenue YoY | -89.2% | 18.4% |
| Net Profit YoY | -23.4% | -55.9% |
| EPS (diluted) | $-1.01 | $0.20 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.7M | $139.2M | ||
| Q3 25 | $4.9M | $134.2M | ||
| Q2 25 | $7.6M | $122.0M | ||
| Q1 25 | $8.1M | $114.8M | ||
| Q4 24 | $15.3M | $117.5M | ||
| Q3 24 | $26.0M | $119.8M | ||
| Q2 24 | $27.4M | $107.2M | ||
| Q1 24 | $39.3M | $81.9M |
| Q4 25 | $-58.1M | $49.4M | ||
| Q3 25 | $-55.8M | $36.4M | ||
| Q2 25 | $-52.8M | $34.2M | ||
| Q1 25 | $-62.3M | $26.9M | ||
| Q4 24 | $-47.1M | $111.9M | ||
| Q3 24 | $-25.9M | $35.9M | ||
| Q2 24 | $-27.2M | $32.1M | ||
| Q1 24 | $-7.2M | $17.8M |
| Q4 25 | — | 63.8% | ||
| Q3 25 | — | 56.3% | ||
| Q2 25 | — | 55.1% | ||
| Q1 25 | — | 53.2% | ||
| Q4 24 | — | 53.9% | ||
| Q3 24 | — | 49.8% | ||
| Q2 24 | — | 53.6% | ||
| Q1 24 | — | 47.8% |
| Q4 25 | -3850.2% | 45.1% | ||
| Q3 25 | -1248.3% | 38.0% | ||
| Q2 25 | -777.4% | 35.1% | ||
| Q1 25 | -847.6% | 30.4% | ||
| Q4 24 | -348.2% | 32.6% | ||
| Q3 24 | -129.1% | 33.1% | ||
| Q2 24 | -127.8% | 36.6% | ||
| Q1 24 | -40.3% | 26.7% |
| Q4 25 | -3513.4% | 35.5% | ||
| Q3 25 | -1127.1% | 27.1% | ||
| Q2 25 | -698.6% | 28.1% | ||
| Q1 25 | -766.0% | 23.4% | ||
| Q4 24 | -308.4% | 95.2% | ||
| Q3 24 | -99.4% | 30.0% | ||
| Q2 24 | -99.3% | 29.9% | ||
| Q1 24 | -18.3% | 21.7% |
| Q4 25 | $-1.01 | $0.20 | ||
| Q3 25 | $-0.99 | $0.15 | ||
| Q2 25 | $-0.94 | $0.14 | ||
| Q1 25 | $-1.13 | $0.11 | ||
| Q4 24 | $-0.87 | $0.45 | ||
| Q3 24 | $-0.48 | $0.15 | ||
| Q2 24 | $-0.51 | $0.13 | ||
| Q1 24 | $-0.14 | $0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $450.3M | $87.6M |
| Total DebtLower is stronger | — | $72.1M |
| Stockholders' EquityBook value | $402.4M | $477.3M |
| Total Assets | $604.0M | $624.2M |
| Debt / EquityLower = less leverage | — | 0.15× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $450.3M | $87.6M | ||
| Q3 25 | $461.4M | $61.4M | ||
| Q2 25 | $453.1M | $90.3M | ||
| Q1 25 | $543.3M | $71.6M | ||
| Q4 24 | $587.4M | $103.1M | ||
| Q3 24 | $574.3M | $86.7M | ||
| Q2 24 | $516.7M | $88.2M | ||
| Q1 24 | $573.9M | $45.3M |
| Q4 25 | — | $72.1M | ||
| Q3 25 | — | $72.4M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $72.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $402.4M | $477.3M | ||
| Q3 25 | $440.8M | $431.2M | ||
| Q2 25 | $392.2M | $398.3M | ||
| Q1 25 | $416.9M | $373.4M | ||
| Q4 24 | $454.8M | $349.0M | ||
| Q3 24 | $483.0M | $231.9M | ||
| Q2 24 | $487.2M | $188.3M | ||
| Q1 24 | $496.6M | $153.7M |
| Q4 25 | $604.0M | $624.2M | ||
| Q3 25 | $655.9M | $568.7M | ||
| Q2 25 | $619.1M | $558.4M | ||
| Q1 25 | $648.1M | $510.6M | ||
| Q4 24 | $711.3M | $488.7M | ||
| Q3 24 | $764.9M | $390.6M | ||
| Q2 24 | $734.3M | $376.4M | ||
| Q1 24 | $779.7M | $350.9M |
| Q4 25 | — | 0.15× | ||
| Q3 25 | — | 0.17× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.21× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-58.2M | $35.6M |
| Free Cash FlowOCF − Capex | $-58.9M | $34.6M |
| FCF MarginFCF / Revenue | -3563.4% | 24.8% |
| Capex IntensityCapex / Revenue | 46.2% | 0.8% |
| Cash ConversionOCF / Net Profit | — | 0.72× |
| TTM Free Cash FlowTrailing 4 quarters | $-212.6M | $27.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-58.2M | $35.6M | ||
| Q3 25 | $-49.2M | $13.3M | ||
| Q2 25 | $-39.7M | $21.1M | ||
| Q1 25 | $-63.1M | $-19.7M | ||
| Q4 24 | $-46.0M | $50.2M | ||
| Q3 24 | $30.7M | $25.0M | ||
| Q2 24 | $-36.2M | $45.6M | ||
| Q1 24 | $-31.9M | $-2.2M |
| Q4 25 | $-58.9M | $34.6M | ||
| Q3 25 | $-49.5M | $-1.1M | ||
| Q2 25 | $-40.2M | $18.7M | ||
| Q1 25 | $-63.9M | $-24.4M | ||
| Q4 24 | $-47.5M | $47.5M | ||
| Q3 24 | $28.4M | $24.0M | ||
| Q2 24 | $-39.5M | $43.6M | ||
| Q1 24 | $-38.3M | $-4.6M |
| Q4 25 | -3563.4% | 24.8% | ||
| Q3 25 | -1000.3% | -0.8% | ||
| Q2 25 | -532.4% | 15.3% | ||
| Q1 25 | -786.4% | -21.2% | ||
| Q4 24 | -311.3% | 40.4% | ||
| Q3 24 | 109.2% | 20.0% | ||
| Q2 24 | -144.1% | 40.7% | ||
| Q1 24 | -97.7% | -5.6% |
| Q4 25 | 46.2% | 0.8% | ||
| Q3 25 | 6.0% | 10.7% | ||
| Q2 25 | 6.4% | 2.0% | ||
| Q1 25 | 9.6% | 4.1% | ||
| Q4 24 | 9.8% | 2.3% | ||
| Q3 24 | 8.8% | 0.9% | ||
| Q2 24 | 11.7% | 1.9% | ||
| Q1 24 | 16.4% | 2.9% |
| Q4 25 | — | 0.72× | ||
| Q3 25 | — | 0.36× | ||
| Q2 25 | — | 0.62× | ||
| Q1 25 | — | -0.73× | ||
| Q4 24 | — | 0.45× | ||
| Q3 24 | — | 0.70× | ||
| Q2 24 | — | 1.42× | ||
| Q1 24 | — | -0.12× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
